Thomas Graney - Vertex Pharmaceuticals CFO, Senior Vice President

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Mr. Thomas Graney is appointed as Chief Financial Officer, Senior Vice President of the company. Mr. Graney is our Senior Vice President and Chief Financial Officer, a position he has held since September 2017. From August 2014 until he joined Vertex, Mr. Graney served as Chief Financial Officer and Senior Vice President of Finance and Corporationrationrate Strategy for Ironwood Pharmaceuticals, Inc. From January 2010 to August 2014, Mr. Graney served as Worldwide Vice President of Finance and Chief Financial Officer of Ethicon, Inc., a maker of surgical medical devices and subsidiary of Johnson and Johnson. From 1994 to 2010, Mr. Graney served in various roles of increasing responsibility at Johnson Johnson, including most recently as Vice President of Finance for JJ Global Supply Chain. Mr. Graney serves on the board of directors of AC Immune SA, a biopharmaceutical company
Age: 52  President Since 2017  MBA    
617 341-6100
Graney holds a BS degree in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Joseph LaRosaRegeneron Pharmaceuticals
John WesolowskiPerrigo Company Plc
Christopher FenimoreRegeneron Pharmaceuticals
Marc CouckePerrigo Company Plc
Ganadhish KamatDr Reddys Laboratories Ltd
Ronald JanishPerrigo Company Plc
Louis YuPerrigo Company Plc
George YancopoulosRegeneron Pharmaceuticals
K RaoDr Reddys Laboratories Ltd
Samiran DasDr Reddys Laboratories Ltd
James DillardPerrigo Company Plc
Raghav ChariDr Reddys Laboratories Ltd
Douglas BoothePerrigo Company Plc
Svend AndersenPerrigo Company Plc
Marion McCourtRegeneron Pharmaceuticals
J RamachandranDr Reddys Laboratories Ltd
Umang VohraDr Reddys Laboratories Ltd
Jay MarkowitzRegeneron Pharmaceuticals
Cartikeya ReddyDr Reddys Laboratories Ltd
Scott JamisonPerrigo Company Plc
Paul WeningerPerrigo Company Plc

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Risk-Return Analysis Now


Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
1 hour ago
Traded for 181.89
Purchased over 100 shares of
1 hour ago
Traded for 30.04
Purchased over 20 shares of
1 hour ago
Traded for 148.32
Also please take a look at World Market Map. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.